The Board of Directors of the Company has approved the divestment by way of sale of its entire equity shareholding in its wholly owned subsidiary- BACC Health Care Private Limited to Inviga ....
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HCG has approved the sale of its entire equity holding in wholly-owned subsidiary BACC Health Care Private Limited to Inviga Healthcare Fund I for INR 37.64 crore. BACC operates in fertility and reproductive healthcare services, which is explicitly stated as non-core to HCG. The transaction is a related party deal as HCG's Promoter and Non-Executive Chairman Dr. B.S. Ajaikumar controls the buyer fund. The deal follows a competitive process and was approved by the Audit Committee and Board on an arm's length basis, with valuation from an independent third-party. BACC contributed INR 60.45 crore revenue (4.45% of HCG standalone) and had net worth of INR 17.53 crore (1.09% of HCG standalone) for FY 2025-26. Completion is expected within 4-5 weeks. HCG intends to reinvest the proceeds in its core cancer services business.
The divestment is positive for HCG as it allows the company to exit a non-core, low-contribution segment and focus capital on its primary cancer care business. The related party nature and relatively small contribution (under 5% of revenue) likely minimises shareholder concern, though the connection between promoter and buyer warrants scrutiny on pricing fairness.